Last reviewed · How we verify

The MP/RP group

Beijing Tiantan Hospital · FDA-approved active Small molecule

The MP/RP group is a Immunotherapy Small molecule drug developed by Beijing Tiantan Hospital. It is currently FDA-approved for Treatment of multiple sclerosis.

The MP/RP group is a type of immunotherapy that targets the immune system to treat various conditions.

The MP/RP group is a type of immunotherapy that targets the immune system to treat various conditions. Used for Treatment of multiple sclerosis.

At a glance

Generic nameThe MP/RP group
SponsorBeijing Tiantan Hospital
Drug classImmunotherapy
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

The MP/RP group works by modulating the immune response to prevent the body from attacking healthy cells, thereby reducing inflammation and improving symptoms. This is achieved through a complex interplay of immune cells and signaling pathways. By targeting specific molecules involved in the immune response, the MP/RP group can help to restore balance to the immune system and promote healing.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about The MP/RP group

What is The MP/RP group?

The MP/RP group is a Immunotherapy drug developed by Beijing Tiantan Hospital, indicated for Treatment of multiple sclerosis.

How does The MP/RP group work?

The MP/RP group is a type of immunotherapy that targets the immune system to treat various conditions.

What is The MP/RP group used for?

The MP/RP group is indicated for Treatment of multiple sclerosis.

Who makes The MP/RP group?

The MP/RP group is developed and marketed by Beijing Tiantan Hospital (see full Beijing Tiantan Hospital pipeline at /company/beijing-tiantan-hospital).

What drug class is The MP/RP group in?

The MP/RP group belongs to the Immunotherapy class. See all Immunotherapy drugs at /class/immunotherapy.

What development phase is The MP/RP group in?

The MP/RP group is FDA-approved (marketed).

What are the side effects of The MP/RP group?

Common side effects of The MP/RP group include Neutropenia, Thrombocytopenia, Anemia.

Related